Who Paid My Doc
Christopher Wang
Hematology & Oncology Birmingham, AL Medical Doctor
NPI 1083856157 CMS profile 1304108
2022 Brookwood Medical Ctr Dr, Ambulatory Care Center, Ste 628, Birmingham, AL 35209
General payments
$22,015
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$119,226
Through program year 2025, Christopher Wang of Birmingham, AL is reported in the CMS Open Payments database as having received $22,015 across 1,136 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $119,226 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 82nd percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $3,313 | 162 | |
| 2024 | General | $3,573 | 187 | |
| 2023 | General | $2,694 | 141 | |
| 2022 | General | $2,892 | 161 | |
| 2021 | General | $4,641 | 171 | |
| 2020 | General | $1,907 | 125 | |
| 2019 | General | $2,994 | 189 |
Beside peers
- Christopher Wang
- Hematology & Oncology median
- Middle half of Hematology & Oncology
- National median
In program year 2025, general payments to Christopher Wang were reported at $3,313. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.
Show as a table
| Year | Christopher Wang | Hematology & Oncology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $2,994 | $529 | $121–$2,516 | $163 |
| 2020 | $1,907 | $339 | $82–$2,213 | $114 |
| 2021 | $4,641 | $263 | $49–$1,965 | $132 |
| 2022 | $2,892 | $416 | $103–$2,395 | $149 |
| 2023 | $2,694 | $542 | $125–$2,646 | $160 |
| 2024 | $3,573 | $692 | $141–$3,008 | $164 |
| 2025 | $3,313 | $683 | $143–$3,154 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 44 drugsPart D claims
1,775
Drug cost
$4,675,530
Branded share of claims
37.1%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Revlimid Lenalidomide | Brand | 90 | $1,220,526 | |
| Calquence Acalabrutinib Maleate | Brand | 51 | $745,802 | |
| Lenalidomide | Generic | 61 | $567,354 | |
| Pomalyst Pomalidomide | Brand | 17 | $382,589 | |
| Ibrance Palbociclib | Brand | 18 | $279,711 | |
| Lumakras Sotorasib | Brand | 12 | $256,906 | |
| Inlyta Axitinib | Brand | 11 | $215,606 | |
| Sprycel Dasatinib | Brand | 21 | $207,472 | |
| Imbruvica Ibrutinib | Brand | 14 | $205,380 | |
| Jakafi Ruxolitinib Phosphate | Brand | 11 | $200,809 |
The 10 drugs with the highest cost, of 44 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,431 Part D prescribers listed as Medical Oncology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 126 billing codesPaid by Medicare
$2,617,603
Medicare patients
606
Services billed
129,434
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 56% | |
| Diabetes | 38% | |
| Chronic kidney disease | 37% | |
| Cancer | 34% | |
| Ischemic heart disease | 33% | |
| Atrial fibrillation | 30% | |
| Depression | 28% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, daratumumab, 10 mg and hyaluronidase-fihj J9144 | Office | 11 | 14,040 | $553,044 |
| Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg J1459 | Office | 23 | 5,010 | $189,396 |
| Injection, ferric derisomaltose, 10 mg J1437 | Office | 66 | 8,100 | $127,601 |
| Injection, denosumab, 1 mg J0897 | Office | 30 | 5,580 | $111,285 |
| Injection, fosnetupitant 235 mg and palonosetron 0.25 mg J1454 | Office | 19 | 68 | $37,036 |
| Injection, dexamethasone sodium phosphate, 1 mg J1100 | Office | 56 | 1,419 | $127 |
| Injection, granisetron hydrochloride, 100 mcg J1626 | Office | 21 | 420 | $103 |
| Infusion, normal saline solution , 1000 cc J7030 | Office | 19 | 32 | $63 |
| Injection, diphenhydramine hcl, up to 50 mg J1200 | Office | 42 | 91 | $56 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 | Office | 13 | 33 | $32 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Payments and prescribing
First 5 of 91 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| ENHERTU |
|
$198 | — | — |
| VENCLEXTA |
|
$156 | — | — |
| KEYTRUDA |
|
$148 | — | — |
| JAKAFI |
|
$109 | 11 | — |
| NINLARO |
|
$102 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
See more in the dashboard: 25 with a free account, all 91 with PatronRecords
1,136 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Hematology & Oncology in Alabama
Amitkumar Mehta
Hematology & Oncology · Birmingham, AL
Pankit Vachhani
Hematology & Oncology · Birmingham, AL
Luciano Costa
Hematology & Oncology · Birmingham, AL
Khaleel Ashraf
Hematology & Oncology · Birmingham, AL
Michael Birrer
Hematology & Oncology · Birmingham, AL
Rudolph Navari
Hematology & Oncology · Birmingham, AL
Related records
Hematology & Oncology in Alabama
Practitioners in the same specialty and state, ranked by reported value.
All Hematology & Oncology
Everyone recorded under this specialty, nationwide.
Doctors in Alabama
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.